| |
| |
|
| Insider
Information: |
Rastetter William H |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
225,281 |
|
|
Indirect Shares
|
1,517,593 |
|
|
| Direct
Value |
$18,735,699 |
|
|
|
Indirect Value
|
$91,979,813 |
|
|
| Total
Shares |
1,742,874 |
|
|
| Total
Value |
$110,715,512 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Biogen Idec Inc |
BIIB |
Executive Chairman, Di... |
2005-02-23 |
50,676 |
2005-02-23 |
373,929 |
Premium* |
|
|
Illumina Inc |
ILMN |
Director |
2015-12-31 |
8,494 |
2015-12-31 |
86,680 |
Premium* |
|
|
Receptos, Inc. |
RCPT |
Director |
2015-08-27 |
0 |
2015-08-25 |
0 |
Premium* |
|
|
Fate Therapeutics Inc |
FATE |
Director |
2022-06-09 |
11,331 |
2022-06-09 |
606,093 |
Premium* |
|
|
Dare Bioscience Inc |
DARE |
Director |
2017-01-03 |
103,039 |
2014-04-15 |
60,307 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
Director |
2015-07-20 |
0 |
2020-02-03 |
390,584 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-01-02 |
51,741 |
2017-02-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-01-02 |
4 |
AS |
$131.47 |
$1,451,927 |
D/D |
(11,044) |
51,741 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-01-02 |
4 |
OE |
$12.98 |
$259,600 |
D/D |
20,000 |
62,785 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-05-01 |
4 |
AS |
$101.43 |
$436,135 |
D/D |
(4,300) |
42,785 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-05-01 |
4 |
OE |
$12.71 |
$96,914 |
D/D |
7,625 |
47,085 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-04-21 |
4 |
AS |
$105.04 |
$633,787 |
D/D |
(6,034) |
39,460 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-04-21 |
4 |
OE |
$12.71 |
$136,823 |
D/D |
10,765 |
45,494 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-04-19 |
4 |
AS |
$105.00 |
$94,819 |
D/D |
(903) |
34,729 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-04-19 |
4 |
OE |
$12.71 |
$20,463 |
D/D |
1,610 |
35,632 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
11,331 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2022-04-01 |
4 |
OE |
$6.66 |
$133,200 |
D/D |
20,000 |
44,750 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2022-04-01 |
4 |
AS |
$94.93 |
$1,018,366 |
D/D |
(10,728) |
34,022 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,681 |
2,681 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2020-03-30 |
4/A |
GA |
$0.00 |
$0 |
I/I |
28,461 |
146,821 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2020-03-30 |
4 |
OE |
$1.37 |
$38,992 |
D/D |
28,461 |
28,461 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2020-03-30 |
4/A |
GD |
$0.00 |
$0 |
D/D |
28,461 |
0 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
225,940 |
390,584 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2019-05-07 |
4/A |
A |
$1.08 |
$100,320 |
I/I |
92,889 |
154,223 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2019-05-07 |
4 |
B |
$1.08 |
$100,320 |
I/I |
92,889 |
154,223 |
2.1 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2018-11-12 |
4 |
A |
$0.00 |
$0 |
I/I |
23,258 |
79,672 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2018-01-24 |
4 |
OE |
$7.05 |
$141,000 |
D/D |
20,000 |
34,250 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2018-01-24 |
4 |
AS |
$90.00 |
$855,000 |
D/D |
(9,500) |
24,750 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2017-12-04 |
4 |
A |
$0.89 |
$61,999 |
I/I |
69,662 |
694,387 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2017-07-25 |
4 |
B |
$0.91 |
$250,000 |
I/I |
274,725 |
624,625 |
2.1 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2017-02-01 |
4 |
AS |
$42.28 |
$454,510 |
D/D |
(10,750) |
14,250 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2017-02-01 |
4 |
OE |
$2.17 |
$54,250 |
D/D |
25,000 |
25,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
